论文部分内容阅读
1989年Choo等应用复杂的分子生物学方法,将丙型肝炎病毒(HCV)克隆出来,相继建立了各种检测方法。由于HCV在血中浓度仅为10~2～10~3CID/ml,所以对HCV的检测需要有较高的敏感性和特异性。兹将现代免疫技术在丙型肝炎诊断中的应用介绍如下。 酶联免疫吸附试验(ELISA) 1989年,由美国Chiron公司首创成酶联免疫吸附试验(ELISA)用重组酵母菌表达的病毒抗原(C—100—3)包被微量塑料板孔检测血清抗—HCV,从而研制出了自发现HCV后的第一代检测慢性丙肝患者血清中抗—HCV的诊断药盒,应用的主要目的是筛选献血员,制止输血后肝炎的发生,但容易出现假阳性。Vander等发现的17％～25％的HCVC
1989 Choo and other applications of complex molecular biology methods, the hepatitis C virus (HCV) cloned out, have established a variety of detection methods. Since HCV concentration in the blood is only 10 ~ 2 ~ 10 ~ 3CID / ml, so the detection of HCV need to have a higher sensitivity and specificity. The application of modern immunization technology in the diagnosis of hepatitis C is introduced as follows. Enzyme-Linked Immunosorbent Assay (ELISA) In 1989, Chiron pioneered the enzyme-linked immunosorbent assay (ELISA) to coat the microtiter plate wells with virus antigen (C-100-3) HCV, and thus developed the first generation of anti-HCV diagnostic kit for detecting serum of patients with chronic hepatitis C since the discovery of HCV. The main purpose of the application is to screen the blood donors and stop the occurrence of post-transfusion hepatitis, but false positives are easy to occur. Vander et al found that 17% to 25% of HCVC